Recently, Biohaven Pharmaceuticals has been making headlines due to its trials on a new drug intended to treat Obsessive Compulsive Disorder (OCD). The new drug is called BHV-0223 and is an oral glutamate modulator. Glutamate is a neurotransmitter that plays an important role in the regulation of anxiety and fear responses. The Phase III trials are designed to assess the safety and efficacy of BHV-0223 in adults with moderate to severe OCD.
The ocd trials biohaven will involve two parts. The first part is a placebo-controlled study in which participants will be given either the drug or a placebo. The primary outcome measure of this part of the trial will be the change in symptoms from baseline to the end of the study period. The second part of the trial will involve an open-label extension study in which participants will be offered the drug for up to 52 weeks. The primary outcome measure of this part of the trial will be the change in symptoms from the initial dose to the end of the study period.
Image Source: Google
The results of the trials are expected to be released in the second half of 2021. If approved, BHV-0223 could be the first drug specifically designed to treat OCD. It is hoped that the drug will provide a safe and effective treatment for millions of people around the world suffering from this debilitating disorder.
In conclusion, Biohaven's recent trials on BHV-0223 have the potential to revolutionize the treatment of OCD. The results of the trials are eagerly awaited and if approved, the drug could provide relief to a huge number of people. It is hoped that the drug will provide safe and effective relief for those suffering from this debilitating disorder.